More pressing for investors is the need to reconcile Newsmax's lofty valuation. With a current $1.7 billion market ...

BOCA RATON, FL / ACCESS Newswire / June 10, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today reported May ...

Newsmax faces audience limits, legal risks, and weak profit potential despite a strong cash position and loyal base. Find out ...

Several options are available to the Holy Father, who has pledged to heal divisions and build bridges within the Church.

At its peak, Newsmax's market cap reached $29 billion, or nearly 170 times the $171 million in revenue it generated in 2024. That meme stock valuation was unsustainable, and Newsmax's price withered ...

BOCA RATON, FL / ACCESS Newswire / June 2, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that ...

As the world economy faces unprecedented shifts, the dynamics of global trade, exchange rates and capital flows are evolving in ways that challenge established economic theory and policy frameworks.

Now that personalised bacteriophage therapies are becoming a reality, the involved field is embracing the expected implementation challenges as outlined. However, the sustainable integration of this ...

Confidence is returning to the advice sectors as almost three quarters of companies feel confident about revenue increasing over the next 12 months. However managing regulatory changes was the ...

Euro zone inflation is on a downward slope and could already hit the ECB's 2% target this month on muted wage growth ... Economists said challenges remained for the German economy, which ...

The enterprise segment took a particular hit with customer downgrades and elevated churn that dented growth metrics. She explained the challenges stem from how the company is fundamentally changing ...

In 2023, the first CRISPR–(Cas9)-based product was approved by the US Food and Drug Administration (FDA): Vertex/CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) for sickle cell disease ...